Janssen acquires CorImmun

Thursday, June 28, 2012 11:09 AM

Janssen-Cilag GmbH has completed the acquisition of CorImmun GmbH, a privately held drug development company in Germany, for an undisclosed upfront payment and a contingent future clinical milestone payment.

Janssen and its affiliates immediately assume full development and global commercialization responsibilities for CorImmun's lead compound, COR-1. COR-1 is a small cyclic peptide currently in early clinical development for the treatment of heart failure. The compound has been shown in preclinical studies to improve heart function by decreasing autoimmune, beta 1 receptor-simulating antibody effects.

"The prevalence of heart failure is rising rapidly, and COR-1 is an early stage development compound with a novel mechanism for treating heart failure that has the potential to improve heart function by suppressing antibodies that can exacerbate this condition," said Peter M. DiBattiste, M.D., global therapeutic area head, cardiovascular disease and metabolism, Janssen R&D. "This acquisition demonstrates Janssen's commitment to investing in innovative science in an area of great unmet medical need, where new therapies can improve the quality of patient care."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs